An Open-Label, Randomized, Phase IIIB Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment beyond Progression of Disease (PD) in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)